Trade Standard BioTools Inc - LAB CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0200 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023512% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.00129% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 1.345 |
| Open | 1.345 |
| 1-Year Change | -46.28% |
| Day's Range | 1.295 - 1.355 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Feb 21, 2025 | 1.2950 | -0.0700 | -5.13% | 1.3650 | 1.3750 | 1.2950 |
| Feb 20, 2025 | 1.3450 | -0.0200 | -1.47% | 1.3650 | 1.3850 | 1.3250 |
| Feb 19, 2025 | 1.3750 | -0.0100 | -0.72% | 1.3850 | 1.4150 | 1.3450 |
| Feb 18, 2025 | 1.3950 | -0.0200 | -1.41% | 1.4150 | 1.4950 | 1.3650 |
| Feb 14, 2025 | 1.4050 | 0.0700 | 5.24% | 1.3350 | 1.4250 | 1.3350 |
| Feb 13, 2025 | 1.3250 | -0.0100 | -0.75% | 1.3350 | 1.3550 | 1.2850 |
| Feb 12, 2025 | 1.3450 | 0.0500 | 3.86% | 1.2950 | 1.3450 | 1.2850 |
| Feb 11, 2025 | 1.2950 | 0.0100 | 0.78% | 1.2850 | 1.2950 | 1.1650 |
| Feb 10, 2025 | 1.3050 | -0.0300 | -2.25% | 1.3350 | 1.3550 | 1.2750 |
| Feb 7, 2025 | 1.3750 | -0.0600 | -4.18% | 1.4350 | 1.4550 | 1.3450 |
| Feb 6, 2025 | 1.4150 | -0.0900 | -5.98% | 1.5050 | 1.5450 | 1.4150 |
| Feb 5, 2025 | 1.4950 | 0.0600 | 4.18% | 1.4350 | 1.5250 | 1.4350 |
| Feb 4, 2025 | 1.4550 | 0.0100 | 0.69% | 1.4450 | 1.4950 | 1.4250 |
| Feb 3, 2025 | 1.4650 | -0.0800 | -5.18% | 1.5450 | 1.5550 | 1.4350 |
| Jan 31, 2025 | 1.5450 | -0.0600 | -3.74% | 1.6050 | 1.6550 | 1.5350 |
| Jan 30, 2025 | 1.6050 | 0.0400 | 2.56% | 1.5650 | 1.6550 | 1.5650 |
| Jan 29, 2025 | 1.5650 | -0.0800 | -4.86% | 1.6450 | 1.6450 | 1.5450 |
| Jan 28, 2025 | 1.6450 | 0.0800 | 5.11% | 1.5650 | 1.6650 | 1.5450 |
| Jan 27, 2025 | 1.5550 | -0.0400 | -2.51% | 1.5950 | 1.6450 | 1.5450 |
| Jan 24, 2025 | 1.6450 | -0.0100 | -0.60% | 1.6550 | 1.6650 | 1.5950 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Standard BioTools Inc Company profile
About Fluidigm Corporation
Fluidigm Corporation creates, manufactures, and markets a range of products and services, including instruments, consumables, reagents, and software that are used by researchers and clinical labs. The Company operates in development, manufacturing, and commercialization of tools for life sciences research. Its technology, mass cytometry is a multiplexed solution to analyze cell-surface and intracellular proteins simultaneously in cell suspensions including blood and disassociated tissues. Its Imaging Mass Cytometry (IMC) technology allows multiplexed imaging to understand the composition of tissue microenvironments at a subcellular 1-micron resolution. It markets technologies and life science tools, including preparatory and analytical instruments for mass cytometry, library prep, single cell genomics, and consumables, including integrated fluidic circuits (ifcs), assays, and reagents. Its analytical instruments include Biomark HD System, EP1 System, and Hyperion Tissue Imager.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Fluidigm Corporation revenues decreased 5% to $130.6M. Net loss increased 12% to $59.2M. Revenues reflect Development revenue segment decrease of 71% to $2.6M, Instruments segment decrease of 7% to $42.5M, United States segment decrease of 16% to $60.2M, Asia-Pacific segment decrease of 7% to $24M. Higher net loss reflects Research and development increase of 4% to $37.9M (expense), Selling.
Equity composition
Common Stock $0.001 Par, 2/11, 19,938,754 auth, 19,938,754 issd. Insiders own approx. 11.14%.
| Industry: | Advanced Medical Equipment & Technology (NEC) |
2 Tower Place
Suite 2000
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US
News
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025
Ripple XRP price prediction: Third-party price target
Discover the ripple (XRP) price predictions for 2025 and beyond, with analyst price targets and CFDs trading strategies on Capital.com
15:29, 6 February 2025
Apple (AAPL) stock price forecast: third-party price target
We looked at the forecasts for Apple stock in 10 years to see where the price would likely be at that point and the challenges the company could face. Read more.
11:22, 6 February 2025
FARTCOIN price prediction: Third-party price target
Read our FARTCOIN price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:18, 29 January 2025
MELANIA coin ($MELANIA) price prediction: Third party price target
Read our MELANIA crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts.
11:33, 22 January 2025
TRUMP coin ($TRUMP) price prediction: third-party price target
Read our TRUMP crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:52, 22 January 2025
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025People also watch
Still looking for a broker you can trust?
Join the 690,000+ traders worldwide that chose to trade with Capital.com